← All indications
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
Drugs by status
Phase 2 trials (52)
- thalidomide
- decitabine
- azacitidine
- methylprednisolone
- mercaptopurine
- venetoclax
- bendamustine
- brentuximab vedotin
- busulfan
- prednisone
- dt388il3
- gemcitabine
- tacrolimus
- l-glutamine
- naltrexone
- beclomethasone
- idarubicin
- nivolumab
- palifermin
- leucovorin
- mb-102
- Flotetuzumab
- milatuzumab
- vincristine
- panobinostat
- allogeneic hematopoietic stem cells
- sirolimus
- cyclosporine
- mycophenolate
- stem cells
- +22 more
Phase 1 trials (27)
- amg-232
- bpx-501
- carfilzomib
- diphenhydramine
- ibuprofen
- durvalumab
- imatinib
- msk-2206
- acetaminophen
- sunitinib
- tetanus-cmv fusion peptide vaccine
- xmab14045
- t-cell depleted lymphocytes
- allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes
- autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes
- idiotype-pulsed allogeneic dendritic cells
- ucart123
- ranitidine
- selenium
- imgn632
- cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
- unicar02-t
- tm123
- cd123 car-t cells
- treggraft
- q702
- mgd024
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (35)
- Celgene
- Millennium Pharmaceuticals
- Genta
- Aronex Pharmaceuticals
- Medsearch
- Medical Research Council
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- University of London
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Northwestern University
- Riverside Haematology Group
- Southwest Oncology Group
- University of Glasgow
- University of Groningen
- University of Leeds
- University of Melbourne
- Utrecht University
- Wayne State University
- West of Scotland Lymphoma Group
- Mayo Clinic
- Capital Medical University
- Peking University
- University of Chicago
- European Organisation for Research and Treatment of Cancer
- Scripps
- +5 more
Organization Involved with Phase 2 Indications (47)
- Poniard Pharmaceuticals
- Immunomedics
- AEterna Zentaris
- Novartis
- CTI BioPharma
- Immune Control
- LifeTime Pharmaceuticals
- Oncotherapeutics
- PrECOG, LLC.
- University of Pennsylvania
- Boston University
- Cancer Biotherapy Research Group
- Case Western Reserve University
- Cancer Trials Ireland
- Cornell University
- European Myeloma Network
- Temple University
- Herbert Irving Comprehensive Cancer Center
- Hoag Memorial Hospital Presbyterian
- Hoosier Cancer Research Network
- Institut Paoli-Calmettes
- Johns Hopkins University
- Loyola University
- Medical College of Wisconsin
- Oregon Health and Science University
- Queen's University, Belfast
- Seoul National University
- Sparrow Regional Cancer Center
- Thomas Jefferson University
- University of Iowa
- +17 more
Organization Involved with Phase 1 Indications (20)
- SmithKline Beecham
- Bristol-Myers Squibb
- Merck
- Ortho Biotech, Inc.
- University of Pittsburgh
- AIDS Malignancy Consortium
- New York University
- Ohio State University
- Rutgers University
- Stanford University
- Swiss Group for Clinical Cancer Research
- University of Medicine and Dentistry of New Jersey
- University of South Florida
- University of Southern California
- University of Bern
- Kantonsspital Graubünden
- Cantonal Hospital of St. Gallen
- Technical University of Dresden
- Johnson and Johnson
- Compugen
Organization Involved with Other Experimental Indications (4)